Exelixis, an oncology-focused biotechnology company, entered into a clinical trial collaboration and supply agreement with Germany-based Merck KGaA, a science and technology company, …
A first glance at this hedge fund’s strategic Q2 moves in biotech sector.
Exelixis, Inc. (NASDAQ:EXEL) announced this morning that it has completed the submission of a supplemental New Drug Application (sNDA) to FDA for Cabometyx …
Dynavax’s Advantage Weighs Towards Heplisav’s Benefits Dynavax Technologies Corporation (NASDAQ:DVAX) shares are racing 5% today after releasing second-quarter earnings. However, this rocket momentum …
Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) investors have a smile on their faces Monday evening, after the drug maker announced positive Phase 2 results for …
William Blair analyst John Sonnier is out highlighting standout insights from his 37th Annual Growth Stock Conference held yesterday. Gilead Sciences, Inc.
Earnings season always brings surprises and serves as a catalyst for companies. In light of yesterday’s reports, Oppenheimer analysts remain cautious on Advanced …
Exelixis, Inc. (NASDAQ:EXEL) announced that the FDA has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma (HCC).
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Exelixis, Inc. (NASDAQ:EXEL) have stirred up interest after Valeant has stepped closer to FDA approval for Vesneo …
